Palisade Bio adds Jordan Zwick to board; authorized shares raised to 450 million
Palisade Bio expanded its board from five to six directors and appointed Jordan Zwick, effective June 10, 2026, who also joined the Audit Committee. At its June 10 annual meeting, stockholders also approved raising authorized common stock from 300,000,000 to 450,000,000 shares, and the amendment took effect on filing with Delaware on June 11, 2026.
Key points
- Jordan Zwick appointed to the board on June 10, 2026, and to the Audit Committee; the board determined he is independent
- Non-employee director initial grant of restricted stock units with a grant value of $566,000, vesting in three equal annual installments
- Authorized common stock increased from 300,000,000 to 450,000,000 shares; stockholders approved it with 128,093,623 votes for and 871,548 against
- Stockholders also approved the amended and restated 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.